Skip to main content

Advertisement

SpringerLink
Log in

Roux-en-Y Gastric Bypass Surgery in Patients with Polycystic Ovary Syndrome and Metabolic Syndrome

  • Original Contributions
  • Published:
Obesity Surgery Aims and scope Submit manuscript

Abstract

Background

We aimed to evaluate the impact of Roux-en-Y gastric bypass (RYGB) surgery on metabolic syndrome-related variables in obese women with polycystic ovarian syndrome (PCOS).

Methods

Thirteen obese women with PCOS (Rotterdam criteria) who met the International Diabetes Federation criteria for metabolic syndrome and who qualified for RYGB were enrolled. Clinical examinations included ovarian ultrasonography and measurement of waist, hip, body mass index and blood pressure. Venous blood samples were taken at the visit before surgery to measure triglyceride, high-density lipoprotein, low-density lipoprotein, fasting glucose, glycated haemoglobin (HbA1c), serum progesterone, allopregnanolone, total testosterone and sex hormone-binding globulin (SHBG) levels. Six months after surgery, patients underwent the same examinations and provided blood samples to analyse the same variables.

Results

At 6 months after surgery, the metabolic syndrome-related variables improved in all patients, except in six patients with anovulatory menstrual cycles who still satisfied the criteria for metabolic syndrome. The metabolic variables normalised and serum progesterone and allopregnanolone levels increased in seven patients with ovulatory cycles. Testosterone and SHBG normalised in all patients at 6 months after surgery. Serum HDL and diastolic blood pressure did not change after surgery. Correlations were found among testosterone, progesterone, allopregnanolone, lipoproteins, triglyceride, fasting glucose and HbA1c levels, which was interpreted as progesterone and its metabolite allopregnanolone may contribute to metabolic abnormalities.

Conclusions

In PCOS patients, normalisation of metabolic dysfunction may be incomplete by 6 months after RYGB surgery, and the start of ovulatory menstrual cycles may indicate normalisation of metabolic dysfunction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2013;6:1–13.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Spritzer PM. Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances. Arq Bras Endocrinol Metabol. 2014;58:182–7.

    Article  PubMed  Google Scholar 

  3. Escobar-Morreale HF. Polycystic ovary syndrome: treatment strategies and management. Expert Opin Pharmacother. 2008;9:2995–3008.

    Article  PubMed  Google Scholar 

  4. Panidis D, Farmakiotis D, Rousso D, et al. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. Fertil Steril. 2008;89:899–906.

    Article  PubMed  Google Scholar 

  5. Vrbikova J, Cifkova R, Jirkovska A, et al. Cardiovascular risk factors in young Czech females with polycystic ovary syndrome. Hum Reprod. 2003;18:980–4.

    Article  PubMed  CAS  Google Scholar 

  6. Escobar-Morreale HF, San Millan JL. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab. 2007;18:266–72.

    Article  PubMed  CAS  Google Scholar 

  7. Diamanti-Kandarakis E. Role of obesity and adiposity in polycystic ovary syndrome. Int J Obes. 2007;31(2):S8–S13. discussion S31-2.

    Article  Google Scholar 

  8. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006;119:812–9.

    Article  PubMed  CAS  Google Scholar 

  9. Vaggopoulos V, Trakakis E, Chrelias C, et al. Comparing classic and newer phenotypes in Greek PCOS women: the prevalence of metabolic syndrome and their association with insulin resistance. J Endocrinol Invest. 2013;36:478–84.

    PubMed  CAS  Google Scholar 

  10. Carmina E, Napoli N, Longo RA, et al. Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J Endocrinol. 2006;154:141–5.

    Article  PubMed  CAS  Google Scholar 

  11. Colquitt JL, Picot J, Loveman E, et al. Surgery for obesity. Cochrane Database Syst Rev. 2009;15:CD003641.

    Google Scholar 

  12. Malik SM, Traub ML. Defining the role of bariatric surgery in polycystic ovarian syndrome patients. World J Diabetes. 2012;3:71–9.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Perez-Torres I, Guarner V, El Hafidi M, et al. Sex hormones, metabolic syndrome and kidney. Curr Top Med Chem. 2011;11:1694–705.

    Article  PubMed  CAS  Google Scholar 

  14. Alemany M. Steroid hormones interrelationships in the metabolic syndrome: an introduction to the ponderostat hypothesis. Hormones. 2012;11:272–89.

    Article  PubMed  Google Scholar 

  15. Netjasov AS, Vujovic S, Ivovic M, et al. Relationships between obesity, lipids and fasting glucose in the menopause. Srp Arh Celok Lek. 2013;141:41–7.

    Article  PubMed  Google Scholar 

  16. Golden SH, Kim C, Barrett-Connor E, et al. The association of elective hormone therapy with changes in lipids among glucose intolerant postmenopausal women in the diabetes prevention program. Metabolism. 2013;62:1313–22.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  17. Moran LJ, Teede HJ, Noakes M, et al. Sex hormone binding globulin, but not testosterone, is associated with the metabolic syndrome in overweight and obese women with polycystic ovary syndrome. J Endocrinol Invest. 2013;36:1004–10.

    PubMed  CAS  Google Scholar 

  18. Prior JC, Elliott TG, Norman E, et al. Progesterone therapy, endothelial function and cardiovascular risk factors: a 3-month randomized, placebo-controlled trial in healthy early postmenopausal women. PLoS One. 2014;9:e84698.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Kalkhoff RK. Metabolic effects of progesterone. Am J Obstet Gynecol. 1982;142:735–8.

    PubMed  CAS  Google Scholar 

  20. Holmberg E, Backstrom T, Johansson M, et al. Allopregnanolone induces a diurnally dependent hyperphagic effect and alters feeding latency and duration in male Wistar rats. Acta Physiol (Oxf). 2013;208:400–9.

    Article  CAS  Google Scholar 

  21. Genazzani AD, Strucchi C, Luisi M, et al. Metformin administration modulates neurosteroids secretion in non-obese amenorrhoic patients with polycystic ovary syndrome. Gynecol Endocrinol. 2006;22:36–43.

    Article  PubMed  CAS  Google Scholar 

  22. Alberti K, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23:469–80.

    Article  PubMed  CAS  Google Scholar 

  23. Rotterdam EA-SPcwg, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–7.

    Article  Google Scholar 

  24. Consultation W. Definition, diagnosis and classification of diabetes mellitus and its complications: Part 1. Diagnosis and classification of diabetes mellitus. Geneva: Wold Health Organization; 1999 [publ. no. WHO/NCD/NCS/99.2].

    Google Scholar 

  25. Timby E, Balgard M, Nyberg S, et al. Pharmacokinetic and behavioral effects of allopregnanolone in healthy women. Psychopharmacology (Berl). 2006;186:414–24.

    Article  CAS  Google Scholar 

  26. Purdy RH, Moore Jr PH, Rao PN, et al. Radioimmunoassay of 3 alpha-hydroxy-5 alpha-pregnan-20-one in rat and human plasma. Steroids. 1990;55:290–6.

    Article  PubMed  CAS  Google Scholar 

  27. Toaff R, Toaff ME, Peyser MR. Infertility following wedge resection of the ovaries. Am J Obstet Gynecol. 1976;124:92–6.

    PubMed  CAS  Google Scholar 

  28. Legro RS, Dodson WC, Gnatuk CL, et al. Effects of gastric bypass surgery on female reproductive function. J Clin Endocrinol Metab. 2012;97:4540–8.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  29. Jamal M, Gunay Y, Capper A, et al. Roux-en-Y gastric bypass ameliorates polycystic ovary syndrome and dramatically improves conception rates: a 9-year analysis. Surg Obes Relat Dis. 2012;8:440–4.

    Article  PubMed  Google Scholar 

  30. Eid GM, Cottam DR, Velcu LM, et al. Effective treatment of polycystic ovarian syndrome with Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2005;1:77–80.

    Article  PubMed  Google Scholar 

  31. Shirling D, Ashby JP, Baird JD. Effect of progesterone on lipid metabolism in the intact rat. J Endocrinol. 1981;90:285–94.

    Article  PubMed  CAS  Google Scholar 

  32. Khokha R, Huff MW, Wolfe BM. Divergent effects of d-norgestrel on the metabolism of rat very low density and low density apolipoprotein B. J Lipid Res. 1986;27:699–705.

    PubMed  CAS  Google Scholar 

  33. Chen FP, Lee N, Soong YK. Changes in the lipoprotein profile in postmenopausal women receiving hormone replacement therapy. Effects of natural and synthetic progesterone. J Reprod Med. 1998;43:568–74.

    PubMed  CAS  Google Scholar 

  34. Melcangi RC, Panzica GC. Allopregnanolone: state of the art. Prog Neurobiol. 2014;113:1–5.

    Article  PubMed  CAS  Google Scholar 

  35. Turkmen SAL, Cengiz Y. Effects of Roux-en-Y gastric bypass surgery on eating behaviour and allopregnanolone levels in obese women with polycystic ovary syndrome. Gynecol Endocrinol. 2014;24:1–5.

    Google Scholar 

  36. Turkmen S, Backstrom T, Wahlstrom G, et al. Tolerance to allopregnanolone with focus on the GABA-A receptor. Br J Pharmacol. 2011;162:311–27.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  37. Genazzani AD, Chierchia E, Rattighieri E, et al. Metformin administration restores allopregnanolone response to adrenocorticotropic hormone (ACTH) stimulation in overweight hyperinsulinemic patients with PCOS. Gynecol Endocrinol. 2010;26:684–9.

    Article  PubMed  CAS  Google Scholar 

  38. Linn ES. Clinical significance of the androgenicity of progestins in hormonal therapy in women. Clin Ther. 1990;12:447–55.

    PubMed  CAS  Google Scholar 

  39. Spellacy WN, Buhi WC, Birk SA. Carbohydrate and lipid metabolic studies before and after one year of treatment with ethynodiol diacetate in “normal” women. Fertil Steril. 1976;27:900–4.

    PubMed  CAS  Google Scholar 

  40. Spellacy WN, Buhi WC, Birk SA. Prospective studies of carbohydrate metabolism in “normal” women using norgestrel for eighteen months. Fertil Steril. 1981;35:167–71.

    PubMed  CAS  Google Scholar 

  41. Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2006;91:492–7.

    Article  PubMed  CAS  Google Scholar 

  42. Haffner SM, Kushwaha RS, Foster DM, et al. Studies on the metabolic mechanism of reduced high density lipoproteins during anabolic steroid therapy. Metabolism. 1983;32:413–20.

    Article  PubMed  CAS  Google Scholar 

  43. Elbers JM, Asscheman H, Seidell JC, et al. Long-term testosterone administration increases visceral fat in female to male transsexuals. J Clin Endocrinol Metab. 1997;82:2044–7.

    PubMed  CAS  Google Scholar 

  44. Lima MM, Pareja JC, Alegre SM, et al. Acute effect of Roux-en-Y gastric bypass on whole-body insulin sensitivity: a study with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95:3871–5.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors thanks research nurse Maria Elander for her help with this study. This study was supported by Forskning & Utveckling (FOU), Landstinget Västernorrland.

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Author information

Authors and Affiliations

  1. Department of Clinical Science, Obstetrics & Gynaecology, Sundsvalls Research Unit, Umeå University, SE-90185, Umeå, Sweden

    Sahruh Turkmen

  2. Department of Clinical Science, Obstetrics & Gynaecology, Umeå Neurosteroid Research Center, Umeå University, SE-90185, Umeå, Sweden

    Sahruh Turkmen, Alebtekin Ahangari & Torbjörn Bäckstrom

Authors
  1. Sahruh Turkmen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alebtekin Ahangari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Torbjörn Bäckstrom
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sahruh Turkmen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Turkmen, S., Ahangari, A. & Bäckstrom, T. Roux-en-Y Gastric Bypass Surgery in Patients with Polycystic Ovary Syndrome and Metabolic Syndrome. OBES SURG 26, 111–118 (2016). https://doi.org/10.1007/s11695-015-1729-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11695-015-1729-0

Keywords

Search

Navigation